NSB
Pharmaceuticals, Biotechnology & Life Sciences
Neuroscientific Biopharmaceuticals
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 3.8K
- Shares on issue
- 389.719M
Neuroscientific Biopharmaceuticals (NSB) company profile
Profile, insiders and operations
Company
AI-generated research profile of Neuroscientific Biopharmaceuticals
biotechnology
pharmaceuticals
stem cells
immunology
ASX
NeuroScientific Biopharmaceuticals Ltd is an Australian biotechnology company focused on developing novel stem cell technologies for immune-mediated inflammatory diseases. Their patented StemSmart™ technology aims to enhance the safety and efficacy of mesenchymal stem cell (MSC) therapies, targeting conditions like Crohn's disease. The company is currently prioritizing a special access program for fistulising Crohn’s disease and plans to advance to clinical trials.
Director trades
8 trades recorded
NSB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required